Company intelligence / Profile preview

Talion

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Talionis is a biotechnology company focused on the discovery and development of next-generation small molecule inhibitors for the treatment of cancer. The company's primary focus is on targeting the KRAS pathway, a well-known driver of various solid tumors that has historically been difficult to target effectively. By leveraging advanced medicinal chemistry and structural biology, Talionis aims to develop highly selective and potent therapies that overcome the limitations of current KRAS inhibitors. The company is currently in the pre-clinical stage, advancing its lead programs toward IND-enabling studies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Talion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talion.

Explore the full profile